Marisa Wexler, MS,  senior science writer—

Basal stem cells taken from the upper part of a patient’s respiratory tract can be expanded in the lab and then transplanted back into their lungs to treat idiopathic pulmonary fibrosis (IPF), according to a recent study. “Our clinical observations herein show that [basal cells] infusion is able to…

Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned to be marketed as Haduvio — in people with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. That achievement was announced by Trevi Therapeutics, the U.S. company…

A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows, suggesting that inhibiting this protein may be an effective strategy for treating the disease. “Our study suggests Runx2 is a potential therapeutic target for preventing or treating pulmonary…

Nerandomilast, an oral treatment being developed by Boehringer Ingelheim, bested a placebo at preserving lung function in adults with progressive pulmonary fibrosis in a Phase 3 study, according to top-line data announced by the company. With those results, nerandomilast met the primary endpoint, or goal, of the study,…

Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people with idiopathic pulmonary fibrosis (IPF). The company has entered into a global licensing agreement with Eli Lilly to advance the development of MTX-463. Mediar will be responsible for…

CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by Calluna Pharma, its developer. “These results are an important step forward in the development of our lead asset, CAL101,…

Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…

In the U.K., patients with idiopathic pulmonary fibrosis (IPF) who live in economically deprived neighborhoods have worse survival outcomes than those living in more affluent areas, according to a recent study. The study also found that patients who live farther away from specialty care centers tend to have worse…

Almee, a behavioral therapy app designed to help ease anxiety in people with pulmonary fibrosis (PF), has been granted breakthrough device designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to medical devices that have the potential to provide a more effective treatment or…

A Phase 2a clinical trial has finished testing the experimental therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF), according to its developer, Endeavor BioMedicines. Endeavor did not include in its announcement any specific data from the trial, but John Hood, PhD, the company’s co-founder, CEO, and…